| Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019 KS Ikuta, LR Swetschinski, GR Aguilar, F Sharara, T Mestrovic, AP Gray, ... The Lancet 400 (10369), 2221-2248, 2022 | 909 | 2022 |
| The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019 KB Tran, JJ Lang, K Compton, R Xu, AR Acheson, HJ Henrikson, ... The Lancet 400 (10352), 563-591, 2022 | 499 | 2022 |
| Global burden of cardiovascular diseases and risks, 1990-2022 GA Mensah, V Fuster, CJL Murray, GA Roth, ... Journal of the American College of Cardiology 82 (25), 2350-2473, 2023 | 242 | 2023 |
| Global burden of chronic respiratory diseases and risk factors, 1990–2019: an update from the Global Burden of Disease Study 2019 S Momtazmanesh, SS Moghaddam, SH Ghamari, EM Rad, N Rezaei, ... EClinicalMedicine 59, 2023 | 159 | 2023 |
| Global investments in pandemic preparedness and COVID-19: development assistance and domestic spending on health between 1990 and 2026 AE Micah, K Bhangdia, IE Cogswell, D Lasher, B Lidral-Porter, ... The Lancet Global Health 11 (3), e385-e413, 2023 | 159 | 2023 |
| Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 JD Steinmetz, KM Seeher, N Schiess, E Nichols, B Cao, C Servili, ... The Lancet Neurology 23 (4), 344-381, 2024 | 144 | 2024 |
| Age–sex differences in the global burden of lower respiratory infections and risk factors, 1990–2019: results from the Global Burden of Disease Study 2019 HH Kyu, A Vongpradith, SB Sirota, A Novotney, CE Troeger, MC Doxey, ... The Lancet Infectious Diseases 22 (11), 1626-1647, 2022 | 133 | 2022 |
| Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990–2021: findings from the Global Burden of Disease Study 2021 GBDA Collaborators The Lancet Haematology, 2023 | 127 | 2023 |
| Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the … AE Schumacher, HH Kyu, A Aali, C Abbafati, J Abbas, ... The Lancet 403 (10440), 1989-2056, 2024 | 115 | 2024 |
| Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in … AJ Ferrari, DF Santomauro, A Aali, YH Abate, C Abbafati, H Abbastabar, ... The Lancet 403 (10440), 2133-2161, 2024 | 102 | 2024 |
| Adolescent transport and unintentional injuries:a systematic analysis using the Global Burden of DiseaseStudy 2019 GBD Collaborators Lancet Public Health, 2022 | 46 | 2022 |
| Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts A Inotai, M Csanadi, G Petrova, M Dimitrova, T Bochenek, T Tesar, K York, ... BioMed Research International 2018, 2018 | 42 | 2018 |
| Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021 NV Bhattacharjee, AE Schumacher, A Aali, YH Abate, R Abbasgholizadeh, ... The Lancet 403 (10440), 2057-2099, 2024 | 34 | 2024 |
| Policy Practices to Maximise Social Benefit from Biosimilars A Inotai, M Csanádi, D Vitezic, I Francetic, T Tesar, T Bochenek, ... Journal of Bioequivalence & Bioavailability 9 (4), 467-472, 2017 | 25 | 2017 |
| The implications of external price referencing on pharmaceutical list prices in Europe M Csanádi, Z Kaló, CPJ Prins, E Grélinger, AM Kiss, FU Fricke, L Fuksa, ... Health Policy and Technology 7 (3), 243-250, 2018 | 24 | 2018 |
| Quo vadis HTA for medical devices in Central and Eastern Europe? Recommendations to address methodological challenges R Daubner-Bendes, S Kovács, M Niewada, M Huic, M Drummond, ... Frontiers in public health 8, 612410, 2021 | 17 | 2021 |
| Cost assessment of inpatient care episodes of stroke in Romania L Lorenzovici, A Szekely, M Csanádi, P Gaál Frontiers in Public Health 8 (December 2020), 605919, 2020 | 17 | 2020 |
| Identifying Patient Access Barriers for Tumor Necrosis Factor Alpha Inhibitor Treatments in Rheumatoid Arthritis in Five Central Eastern European Countries A Inotai, D Tomek, M Niewada, L Lorenzovici, M Kolek, J Weber, ... Frontiers in Pharmacology 11 (Article 845), 2020 | 12 | 2020 |
| Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment A Zemplényi, K Tachkov, L Balkanyi, B Németh, ZI Petykó, G Petrova, ... Frontiers in Public Health 11 (2023), https://doi.org/10.3389/fpubh.2023.10881, 2023 | 11 | 2023 |
| Prioritization of implementation barriers related to integrated care models in Central and Eastern European countries M Csanádi, Z Kaló, M Rutten-van Molken, W Looman, M Huic, D Ercevic, ... Health Policy 126 (11), 1173-1179, 2022 | 10 | 2022 |
Zoltán KalóCenter for Health Technology Assessment, Semmelweis University; Syreon Res在 semmelweis.hu 的电子邮件经过验证
